Skip to Content

Pertuzumab Disease Interactions

There are 5 disease interactions with pertuzumab:


HER2 inhibitors (Includes pertuzumab) ↔ pulmonary toxicity

Severe Potential Hazard, Moderate plausibility. Applies to: Pulmonary Impairment

Pulmonary toxicity, sometimes fatal has been reported with agents that block HER2 activity. Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest may be at increased risk of pulmonary toxicity and appear to have more severe toxicity. Patients should be monitored for pulmonary symptoms. Permanently discontinue treatment with these agents in patients diagnosed with interstitial lung disease or pneumonitis and institute appropriate care.


HER2 inhibitors (Includes pertuzumab) ↔ CHF

Moderate Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure, Hypertension, History - Myocardial Infarction, Arrhythmias, Myocardial Infarction, Post MI Syndrome

Decreases in left ventricular ejection fraction (LVEF) have been reported with agents that block HER2 activity. Patients who have received prior anthracyclines, those who received anthracycline after stopping therapy with agents that block HER2 activity, or patients who received prior radiotherapy to the chest area may be at higher risk of decreased LVEF. Therapy with these agents should be administered cautiously in patients with prior history of heart conditions. Evaluate cardiac function before, during and upon completion of treatment. Discontinue treatment with agents that block HER2 activity as appropriate, and for a confirmed clinically significant decrease in left ventricular function, or if the LVEF has not improved or has declined further, unless the benefits for the individual patient outweigh the risks.


HER2 inhibitors (Includes pertuzumab) ↔ peripheral neuropathy

Moderate Potential Hazard, Moderate plausibility. Applies to: Peripheral Neuropathy, Diabetes Mellitus

Peripheral neuropathy has been reported with the use of agents that block HER2 activity. Patients experiencing peripheral neuropathy may require temporary interruption, dose reduction, or treatment discontinuation of these agents. Withhold dosing temporarily for patients experiencing Grade 3 or 4 peripheral neuropathy until resolution. Close monitoring is recommended when using these agents in patients at risk, and all patients should be monitored on an ongoing basis for signs or symptoms of neurotoxicity.


HER2 inhibitors (Includes pertuzumab) ↔ thrombocytopenia

Moderate Potential Hazard, Moderate plausibility. Applies to: Thrombocytopenia

Thrombocytopenia has been reported with the use of agents that block HER2 activity. Monitor platelet counts prior to initiation of therapy and prior to each dose. If appropriate modify the dose according to clinical guidelines. Patients with decreased platelet count and patients on anti-coagulant treatment should be closely monitored during treatment with these agents.


Pertuzumab (Includes pertuzumab) ↔ renal dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

No dose adjustment of pertuzumab is necessary in patients with mild or moderate renal impairment. Caution should be exercised if pertuzumab is used in patients with severe renal impairment as there is limited pharmacokinetic data available. Clinical monitoring of renal function is recommended.

Pertuzumab drug interactions

There is 1 drug interaction with pertuzumab

Pertuzumab alcohol/food interactions

There is 1 alcohol/food interaction with pertuzumab

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.